Coya Therapeutics to Present Neurofilament Light Chain (NfL) Biomarker Stratification Methodology in the ALSTARS Trial to Minimize the Impact of Heterogeneity in ALS Clinical Trials at the 2026 Annual NEALS Meeting
Coya Therapeutics will present a poster at the 2026 Annual NEALS Meeting describing a 3-tiered neurofilament light chain (NfL) stratification methodology for its Phase 2/3 ALSTARS trial of COYA 302 in ALS. The company believes stratifying patients by baseline NfL balances prognostic risk across arms, reduces heterogeneity, and may improve the signal-to-noise ratio for the ALSFRS-R primary endpoint.
Key figures
- Drug Name
- COYA 302
- Phase Of Trial
- Phase 2/3
- Subjects randomized
- approximately 120
- Extension phase weeks
- 24
- Treatment phase weeks
- 24
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.